Nautilus Bio Stock (NASDAQ:NAUT)

Forecast Ownership Financials Chart Transcripts

Previous Close

$1.35

52W Range

$0.62 - $2.92

50D Avg

$0.84

200D Avg

$0.97

Market Cap

$180.62M

Avg Vol (3M)

$385.11K

Beta

1.33

Div Yield

NAUT Company Profile

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

134

IPO Date

Aug 07, 2020

Website

NAUT Performance

NAUT Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	-	$-76.15M	$-63.62M
Net Income	$-70.78M	$-63.67M	$-63.74M
EBITDA	-	$-74.30M	$-54.51M
Basic EPS	$-0.56	$-0.51	$-0.51
Diluted EPS	$-0.56	$-0.51	$-0.51

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 01, 25 | 8:30 AM

Q1 25Apr 29, 25 | 8:30 AM

Q4 24Feb 28, 25 | 8:30 AM

Peer Comparison

Ticker	Company
IRD	Opus Genetics, Inc.
TCRX	TScan Therapeutics, Inc.
SRZN	Surrozen, Inc.
AGEN	Agenus Inc.
SEER	Seer, Inc.
INO	Inovio Pharmaceuticals, Inc.
HURA	TuHURA Biosciences, Inc.
VTGN	VistaGen Therapeutics, Inc.
CGTX	Cognition Therapeutics, Inc.
CNTX	Context Therapeutics Inc.